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Abstract
Introduction: Long pentraxin 3 (PTX3) is an acute-phase protein secreted by various cells, including leukocytes and
endothelial cells. Like C-reactive protein (CRP), it belongs to the pentraxin superfamily. Recent studies indicate that high
levels of PTX3 may be associated with mortality in sepsis. The prognostic value of plasma PTX3 in bacteremic patients is
unknown.
Methods: Plasma PTX3 levels were measured in 132 patients with bacteremia caused by Staphylococcus aureus,
Streptococcus pneumoniae, b-hemolytic streptococcae and Escherichia coli, using a commercial solid-phase enzyme-linked
immunosorbent assay (ELISA). Values were measured on days 1–4 after positive blood culture, on day 13–18 and on
recovery.
Results: The maximum PTX3 values on days 1–4 were markedly higher in nonsurvivors compared to survivors (44.8 vs
6.4 ng/ml, p,0.001) and the AUCROC in the prediction of case fatality was 0.82 (95% CI 0.73–0.91). PTX3 at a cut-off level of
15 ng/ml showed 72% sensitivity and 81% specificity for fatal disease. High PTX3 (.15 ng/ml) was associated with
hypotension (MAP ,70 mmHg)(OR 7.9;95% CI 3.3–19.0) and high SOFA score ($4)(OR 13.2; 95% CI 4.9–35.4). The CRP level
(maximum value on days 1 to 4) did not predict case fatality at any cut-off level in the ROC curve (p = 0.132). High PTX3
(.15 ng/ml) remained an independent risk factor for case fatality in a logistic regression model adjusted for potential
confounders.
Conclusions: PTX3 proved to be a specific independent prognostic biomarker in bacteremia. PTX3 during the first days after
diagnosis showed better prognostic value as compared to CRP, a widely used biomarker in clinical settings. PTX3
measurement offers a novel opportunity for the prognostic stratification of bacteremia patients.
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Introduction
Bacteremia is a common disease associated with significant
mortality [1]. Early categorization of patients with different
prognoses is difficult in the absence of a timely sensitive and
specific biomarker. Although C-reactive protein (CRP) has been
widely used as a prognostic marker in infectious diseases, its
prognosic value in bacteremia and sepsis is weak [2].
Pentraxins are multi-functional pattern-recognition receptors
(PRR) interacting with selected viral, fungal and bacterial
components. Long pentraxin 3 (PTX3), CRP and serum amyloid
P (SAP) are the key members of the pentraxin superfamily.
Although the long (PTX3) and short pentraxins (CRP and SAP)
share common sequences they are encoded by different genes and
are differentially regulated. CRP is produced in the liver, while
PTX3 is an inflammatory mediator produced by various cells in
peripheral tissues, for example macrophages, dendritic cells,
endothelial cells, ovarian granulosa cells, fibroblasts, adipocytes
and smooth muscle cells in response to the proinflammatory
signals lipopolysaccharide (LPS), interleukin-1 (IL-1) and tumor
necrosis factor-alfa (TNF-alfa) and Toll-like receptor activation
[3,4]. PTX3 behaves as an acute-phase protein, as its blood levels,
low in normal conditions (,2 ng/ml in humans), increase rapidly
in the plasma during inflammation (sepsis, endotoxin shock and
other inflammatory conditions) [3]. PTX3 released in response to
microbial recognition can bind specific pathogens such as fungi,
bacteria and viruses, promoting phagocytosis and subsequent
clearance of the pathogen via its binding to complement
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component C1q to induce classical complement activation [3,5,6].
Thus, PTX3 has a non-redundant role in the regulation of the
innate immune response by contributing to the opsonization and
clearance of apoptotic or necrotic cells [3].
In recently published studies, a high PTX3 level has been shown
to be associated with mortality in severe sepsis and septic shock
[7], and to be an early indicator of shock in severe meningococcal
disease [8]. Elevated plasma levels of PTX3 predict disease
severity in dengue virus infection [9] and in leptospirosis [10]. In
critically ill patients PTX3 correlates with severity of disease and
infection [11]. It has been shown to predict bloodstream infection
and severe disease in febrile patients admitted to emergency
departments [12] and indicates acute respiratory distress syndrome
(ARDS) in critically ill patients [13]. PTX3 has been shown to act
as biomarker of acute lung injury [14]. However, to the best of our
knowledge no study has investigated the prognostic value of PTX3
in a cohort of patients with bacteremic infection.
We have previously studied prognostic factors associated with
case fatality in bacteremia and found obesity (BMI$30) and
smoking to be associated with poor outcome [15]. We sought here
to assess the prognostic value of plasma PTX3 in relation to other
known prognostic factors in bacteremic patients. The prognostic
values of two members of the pentraxin superfamily, CRP and
PTX3, were compared. We show that PTX3 measurement may
offer novel opportunities for the early prognostic stratification of
bacteremic patients.
Materials and Methods
Patients
The study material comprised 132 adult patients with
bacteremia admitted to Tampere University Hospital, Tampere,
Finland, from June 1999 to February 2004 (Table 1). Patients were
recruited from the emergency room, intensive care unit (ICU) and
medical wards of the hospital. Patient recruitment, clinical data
collection and sample collection were prospective. Samples for
PTX3 were analyzed after hospitalization.
In our hospital blood cultures are routinely taken in cases with
symptoms or signs of systemic infection (fever or hypothermia,
tachycardia or tachypnea combined with leukocytosis or leukope-
nia and/or elevated C-reactive protein (CRP)). The BACTEC
9240 (BD Diagnostic Systems, Sparks, MD, USA) blood culture
system was used with standard media. Patients were identified
according to microbiological blood culture finding, and only those
with bacteremia caused by S. aureus, Str. pneumoniae, b-hemolytic
streptococcus or E. coli, the most common causative organisms in
community-acquired bacteremia, were included in the study, other
microbes being excluded beforehand. Blood culture-negative
patients with or without sepsis syndrome and those not consenting
were not included. All patients included in the study had verified
infection. Only patients at least 16 years of age were enrolled. The
clinicians (J.S. or J.L.) were informed by the clinical microbiologist
(R.V.) of a positive blood culture from Mondays to Thursdays and
the patients were enrolled in the study whenever possible to adjust
to the daily schedule. We were able to recruit zero to two patients
per week during the study period. Since the clinicians had no
knowledge of details regarding the patients or their disease severity
prior to recruitment, selection was based solely on the blood
culture finding. Upon notification by the clinical microbiologist the
clinicians (J.L. and J.S.) asked patients to participate and
interviewed and examined those consenting. Information was
gathered from hospital records at the time of a hospital visit and
hospital records were also reviewed subsequent to hospitalization
(R.H.). Altogether 149 out of 152 patients agreed to participate.
Samples for PTX3 determinations during 1–4 days after positive
blood culture were available in 132 cases, and these patients were
recruited as the final study population. The study was approved by
the Ethics Committee of Tampere University Hospital. Written
informed consent was obtained from patients or first-degree
relatives.
Underlying diseases and chronic conditions
Chronic diseases and sources of bacteremia were registered.
Calculation of body mass index (BMI, kg/m2) was based on weight
and height as reported by the patient on admission. Patients were
defined as obese if their BMI was $30 kg/m2. Alcohol abuse was
defined as consumption of 300 g absolute alcohol per week or a
known social or medical problem due to alcohol use. Patients were
defined as current smokers and nonsmokers, i.e. those who had
never smoked or had stopped smoking. McCabe classification [16]
was used to determine the severity of any underlying disease.
Collection of clinical and laboratory data
Clinical data and laboratory findings were registered on
admission and during 6 consecutive days. Alterations in mental
Table 1. Baseline characteristics of the study population (132
patients).
Character
Age, median (range) 62 (18–93 years)
Gender (female/male) 62/70
Causative organism
S. aureus 32 (24%)
Str. pneumoniae 37 (28%)
B- hemolytic streptococcus 22 (17%)
E. coli 41 (31%)
Focus of infection (one patient may have
several focuses)
Lung 33 (25%)
Skin 33 (25%)
Urinary 29 (22%)
Osteomyelitis/spondylitis 13 (10%)
Other or unknown focus 41 (31%)
BMI (kg/m2), median (range)a 26 (15–39)
Diabetes mellitus (type 1 or 2) 33 (25%)
Current smokingb 33 (28%)
Alcohol abuse 21 (16%)
Cancer (solid or hematological) 23 (17%)
At least one chronic disease 107 (81%)
McCabe class II or IIIc 22 (17%)
Cardiac diseased 41 (31%)
SOFA score, median (quartiles)e 2 (1–6)
ICU treamentf 42 (32%)
Died (d-30 case fatality) 18 (14%)
aBMI data available on 101 patients,
bsmoking data available on 120 patients,
crapidly or ultimately fatal disease,
dvalvular, coronary artery disease, heart failure or cardiac myopathy,
esequential organ failure assessment,
fintensive care unit.
doi:10.1371/journal.pone.0017653.t001
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status were evaluated on the Glasgow Coma Scale (GCS), possible
mechanical ventilation and the need for intensive care unit (ICU)
treatment were recorded. Mean arterial pressure (MAP) ((systol-
ic+2 x diastolic blood pressure)/3) and SOFA score (sequential
organ failure assessment) [17] were calculated. The maximum
SOFA score (days 0–6) for every patient was used in analysis.
Disease severity was assessed by SOFA score, severe disease being
defined as a score$4. Laboratory tests included plasma C-reactive
protein (CRP, mg/l), blood platelets (x109/l), plasma bilirubin
(mmol/l), plasma creatinine level (mmol/l) and blood leukocyte
count (x109/l). The case fatality rate was studied within 14 and 30
days after a positive blood culture (d–14 and d–30 case fatality).
Determination of PTX3 plasma levels
EDTA plasma samples for PTX3 determination were taken
during patients hospitalization and were stored at 270u until
analyzed. PTX3 concentrations were determined in EDTA-
plasma using a commercial solid-phase enzyme-linked immuno-
sorbent assay (ELISA) according to the manufacturer’s instructions
(Quantikine DPTX 30; R&D Systems Inc., Minneapolis, USA).
Samples in which the PTX3 concentration exceeded the detection
range (n= 59) were serially diluted in assay diluent until they
reached the dynamic range of the assay. According to the
manufacturer, the mean detection limit for PTX3 is 0.025 ng/ml
and the assay exhibits no cross-reactivity with either CRP or serum
amyloid P. The plates were read with a Multiskan Ascent
photometer (Thermo Scientific, Waltham, MA, USA) at 450 nm
and corrected for readings at 540 nm.
Samples for PTX3 determinations were taken in the acute
phase (days 1 to 4) (n = 132 patients), on day 13–18 (13–18 days
after blood culture) (n = 73 patients) and on recovery (.25 days
after positive blood culture) (n = 89 patients). Multiple samplings in
the same patient were always performed on separate days. The
maximum values for PTX3 for every patient measured during 1–4
days after positive blood culture were determined. Since patient
recruitment was based on blood culture, which only became
positive the following day, no samples for PTX3 were available on
day 0 (blood culture day).
Statistical analysis
An SPSS package (version 7.5 and version 10) was used for
statistical analyses and a two-sided p-value,0.05 was taken as cut-
off for statistical significance. Categorical data were analyzed by
X2 test or Fishers exact test when appropriate, nonparametric data
by Mann-Whitney U-test or Kruskal-Wallis test. A logistic
regression model was used to study the independent effect of high
PTX3 activity on mortality models adjusted for potential
confounders. Odds ratios (ORs) were expressed with their 95%
confidence intervals (CI). The survival curve was calculated using
the Kaplan-Meier method and survival differences between groups
were compared using the log rank test. The accuracy of maximum
PTX3 value and CRP in predicting case fatality was evaluated
using ROC curves [18]. In this method, a test which is perfect has
100% sensitivity and no false-positives (1-specificity = 0) and will
have an area under the curve (AUC) of 1.0, whereas a test of no
diagnostic value would have an AUC of 0.5. The 95% confidence
intervals were calculated.
Results
Baseline characteristics of bacteremia patients are shown in
Table 1. All subjects were treated with an empiric antibiotic
regimen, and when necessary antimicrobial treatment was
changed according to culture results. In all patients the causative
organism proved susceptible to the first empiric antibiotic
treatment selected on admission. Patients received antimicrobial
therapy for a median of 17 days after blood culture.
PTX3 values in bacteremic patients
The median plasma PTX3 value in the acute phase (maximum
value 1 to 4 days after blood culture) was 7.8 ng/ml (interquartile
range 3.7–17.5 ng/ml) and 3.0 ng/ml on days 13–18 after blood
culture (interquartile range 1.2–6.6 ng/ml). Values decreased on
recovery; the median value .25 days after blood culture was
1.1 ng/ml (interquartile range 0.5–2.0 ng/ml). Of chronic condi-
tions, alcohol abusers had higher PTX3 values compared to
patients without a history of alcohol abuse (maximum values 1 to 4
after blood culture 12.6 ng/ml compared to 7.3 ng/ml, p = 0.036,
respectively). However, there was no difference between groups of
patients in PTX3 levels stratified by other chronic conditions, age,
sex or causative organism (data not shown).
PTX3 and the outcome of bacteremia
Median PTX3 values were significantly higher in nonsurvivors
compared to survivors on days 1 to 2 (51.2 vs 9.7 ng/ml, p=0.008), on
day 3 (34.9 vs 5.3 ng/ml, p,0.001) and on day 4 (24.6 vs 4.5 ng/ml,
p,0.001) after the initial diagnosis (blood culture day) (Table 2).
Maximum PTX3 values on days 1 to 4 after the initial diagnosis (blood
culture day) were significantly higher in nonsurvivors compared to
survivors (median values 44.8 vs 6.4 ng/ml, p,0.001).
Table 2. Pentraxins in patients with bacteremiaa.
Days after
diagnosis Plasma PTX3 value (ng/ml), median (quartiles) p-value Plasma CRP value (mg/l), median (quartiles) p-value
Nonsurvivors n=18 Survivors n=118 Nonsurvivors n=18 Survivors n =118
Day 1–2 51.2 (40.8–113.5) 9.7 (6.4–17.7) 0.008 280 (206–368) 234 (158–335) 0.132
Day 3 34.9 (12.3–63.2) 5.3 (2.6–13.1) ,0.001 193 (163–238) 144 (68–232) 0.05
Day 4 24.6 (11.0–63.8) 4.5 (2.7–8.9) ,0.001 129 (105–160) 102 (48–168) 0.100
Maximum value
(days 1 to 4)
44.8 (10.7–69.4) 6.4 (3.4–13.5) ,0.001 280 (206–368) 236 (155–334) 0.132
Plasma long pentraxin 3 (PTX3) and short pentraxin C-reactive protein (CRP) values 1 to 4 days after blood culture (diagnosis) in bacteremia nonsurvivors and in
survivors.
aPTX3 values available for 34 patients (5 nonsurvivors and 29 survivors) on day 1–2, 81 patients (12 nonsurvivors and 69 survivors) on day 3, 104 patients (17
nonsurvivors and 87 survivors) on day 4. CRP values available for 126 patients (18 nonsurvivors and 108 survivors) on day 1–2, 85 patients (12 nonsurvivors and 73
survivors) on day 3, 109 patients (15 nonsurvivors and 94 survivors) on day 4.
doi:10.1371/journal.pone.0017653.t002
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The optimal cut-off value for the maximum PTX3 values on
days 1–4 in predicting fatal disease was estimated using ROC
curve, illustrated in Figure 1. The PTX3 value at a cut-off level of
15 ng/ml showed a sensitivity of 72% and a specificity of 81% in
detecting fatal disease, and this cut-off point was used to classify
patients into those with high or low PTX3 value. High PTX3
values were associated with several endpoints indicative of severe
disease (Table 3). Figure 2 shows cumulative 30-d survival in
bacteremia patients with maximum plasma long pentraxin 3
(PTX3) level (1–4 days after blood culture) .15 ng/ml compared
to those with #15 ng/ml.
The independent effect of high (.15 ng/ml) maximum PTX3
value on case fatality was studied in a logistic regression model
adjusted for potential confounders (Table 4). High maximun
PTX3 value was studied together with one confounder at a time in
a logistic regression model, as there were only 18 patients who
died. The following grouping variables have previously been
shown to be associated with case fatality in a univariate model in
this material: obesity, smoking, alcohol abuse, and high SOFA
score ($4)[15]. High PTX3 detected on days 1–4 after blood
culture retained its significance in the logistic regression model in
all combinations. Obesity and high SOFA score ($4) also
remained independent factors associated with case fatality when
studied together with high PTX3.
CRP and the outcome of bacteremia
The CRP level (maximum value on days 1 to 4) did not predict
case fatality at any cut-off level in the ROC curve (p= 0.132)
(Figure 1). The AUCROC for CRP (days 1 to 4 after blood culture)
was 0.61 (95% CI 0.49–0.73). Thus, the optimal cut-off for CRP in
detecting fatal disease could not be determined.
Discussion
The results presented here show high PTX3 values during the
first days after diagnosis to be independently associated with case
fatality in patients with bacteremia. High PTX3 values were
associated with several variables indicative of severe disease.
Compared to CRP, a member of the same pentraxin superfamily,
PTX3 may act as a more specific prognostic marker in bacteremic
patients.
To the best of our knowledge, no previous study has investigated
PTX3 in patients with blood culture-proven bacteremic infection.
The present findings evidence the value of PTX3 in patients with
blood culture-proven bacteremia caused by the four microbial
organisms most commonly encountered in clinical practice. The
study involved patients with non-severe disease and those admitted
to the ICU due to severe infection, which enables study of the
value of PTX3 in patients with distinct outcomes. In accord with
the present findings, a high PTX3 level has previously been shown
to be associated with mortality in severe sepsis and septic shock [7]
and to be an early indicator of shock in severe meningococcal
disease [8]. Furthermore, PTX3 is elevated in critically ill patients
and in febrile patients admitted to the emergency room,
correlating with severity of disease and infection in these patient
groups [11,12]. The present results thus confirm those of previous
studies on the prognostic value of PTX3 in infectious diseases. The
study shows that PTX3 may be used to predict all variables
indicative of severe disease, i.e. hypotension, mechanical ventila-
tion, low platelet count, high SOFA score, need of ICU treatment
and renal failure.
PTX3 behaves as an acute-phase response protein, its blood
levels being low in normal conditions (,2 ng/ml in humans) but
increasing rapidly in inflammatory and infectious conditions [3].
In accord with this, the PTX3 values in the present study were
high in the acute phase and decreased on recovery. Only the day
1–4 values were included in the final ROC analysis, as the PTX3
values on the first days following blood culture (i.e. diagnosis) are
most unlikely to be related to conditions other than bacteremia per
se. The initially high values already 1 to 2 days after clinical
Figure 1. PTX3 and CRP ROC curves. Receiver operating
characteristic (ROC) curves for maximal plasma long pentraxin 3
(PTX3) and C-reactive protein (CRP) levels detected on days 1–4 after
positive blood culture in relation to case fatality in bacteremia patients.
doi:10.1371/journal.pone.0017653.g001
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suspicion of bacteremia (after blood culture) may reflect the central
role of PTX3 in the first-step innate immune response, acting as a
pattern recognition receptor, with subsequent activation of
complement cascade and pathogen opsonization.
In the present material, the values did not differ significantly
between patients with infection caused by the four different culprit
organisms. The precise clinical implications of PTX3 in infectious
diseases remain elusive. In animal models, PTX3 even been found
to protect from endotoxic shock and sepsis, but controversial
results have also been published, highlighting the delicate balance
among the various mediators which control the inflammatory
response [5,19,20]. There is evidence suggesting that PTX3 may
contribute to acute lung injury (ALI) during inflammation, and a
correlation between PTX3 expression and the severity of the lung
injury has been documented [14]. On the other hand, previous
Table 3. Clinical characteristics of patients stratified by maximum plasma long pentraxin 3 PTX3 value (1 to 4 days after blood
culture).
Characteristic
High PTX3
(.15 ng/ml)
N=35
Low PTX3
(#15 ng/ml)
N=97 OR (95% CI) p-value
Died (d-30 case fatality) 13 (37%) 5 (5%) 10.9 (3.5–33.7) ,0.001
Died (d-14 case fatality) 11 (31%) 1 (1%) 44.0 (5.4–357.7) ,0.001
Hypotensive P,70 mmHg) 26 (74%) 26 (27%) 7.9 (3.3–19.0) ,0.001
Needed ICU staya 25 (71%) 17 (18%) 11.8 (4.8–29.0) ,0.001
Needed vasopressives 20 (57%) 6 (6%) 20.2 (7.0–58.6) ,0.001
Lowered Glasgow coma scale (,15) 26 (74%) 27 (28%) 7.5 (3.1–18.0) ,0.001
Needed mechanical ventilation 16 (46%) 4 (4%) 19.6 (5.9–65.1) ,0.001
Highest SOFA score$4b 29 (83%) 26 (27%) 13.2 (4.9–35.4) ,0.001
Lowest MAPc (mmHg), median (quartiles) 59 (52–73) 78 (68–92) $ ,0.001
Highest SOFA score, median (quartiles) 9 (4–13) 2 (0–4) $ ,0.001
Highest bilirubin level (mmol/l), median (quartiles) 23 (16–74) 17 (13–29) $ 0.006
Highest creatinine level (mmol/l), median (quartiles) 146 (91–219) 98 (75–174) $ 0.028
Median neutrophil count (x109/l) (quartiles) (n = 112) 9.3 (8.1–13.2) 6.7 (3.8–9.8) $ ,0.001
Lowest platelet count (x109/l), median (quartiles) 86 (28–181) 171 (113–235) $ ,0.001
aintensive care unit,
bsequential organ failure assessment,
cmean arterial pressure, $continuous variable (OR and CI cannot be applied).
doi:10.1371/journal.pone.0017653.t003
Table 4. The independent effect of high maximum plasma
long pentraxin 3 (PTX3) value (.15 ng/ml) on days 1–4 on
case fatality in a logistic regression model adjusted for
potential confounders.
Variables in the logistic
regression model
Odds ratio for high PTX3
(ng/ml)
High PTX3 (.15 ng/ml) +
male sex and age 11.3 (3.5–36.2)
obesity ($30 kg/m2)a 11.1 (2.3–54.1)
alcohol abuse 10.0 (3.2–31.2)
current smokingb 9.9. (2.7–36.4)
McCabe class II or III 10.9 (3.5–34.0)
SOFA score ($4)c 4.8 (1.4–16.4)
Obesity, smoking and alcohol abuse are included in the model as they proved
to be factors significantly associated with case fatality in the univariate model in
this material [15].
aBMI data available on 101 patients, obesity also remained a significant factor
associated with case fatality in the logistic regression model.
bSmoking data available on 120 patients.
cSequential organ failure assessment score; also remained a significant factor
associated with case fatality in the logistic regression model.
doi:10.1371/journal.pone.0017653.t004
Figure 2. PTX3 survival curves. Cumulative 30-d survival in
bacteremia patients with maximum plasma long pentraxin 3 (PTX3)
level (1–4 days after blood culture) .15 ng/ml compared to those with
#15 ng/ml. The survival curve was calculated using the Kaplan-Meier
method, and survival differences between groups were compared by
log-rank test.
doi:10.1371/journal.pone.0017653.g002
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studies have shown that PTX3 is able to up-regulate tissue factor, a
critical factor in the pathogenesis of coagulation/fibrinolysis
dysregulation in sepsis [7,8]. Sprong and associates have shown
that PTX3 levels correlate significantly negatively with fibrinogen
levels in sepsis. PTX3 may thus contribute to the pathological
coagulation process in this condition [8]. High PTX3 concentra-
tion in severe disease may also reflect the role of pentraxins in the
clearance of apoptotic cells.
The currently available biomarkers or nonspecific physiologic
criteria for the sepsis syndrome or the systemic inflammatory
response syndrome (SIRS) do not adequately identify patients who
might benefit either from conventional antimicrobial therapies or
from therapies targeting specific mediators of inflammation, i.e.
recombinant human activated protein C (rhAPC) [21]. Prognosis
of patients is important in risk stratification and for efficient use of
hospital resources [21,22]. The prognostic value of PTX3 as
evaluated by ROC curve was better than that for CRP during the
first days after diagnosis of bacteremic infection. This finding is in
accord with those of a recent study in patients with severe sepsis
and septic shock, showing the prognostic superiority of PTX3 over
CRP [7]. Although both belong to the same pentraxin family, long
pentraxins (i.e. PTX3) differ from short (SAP and CRP) in several
respects, including their gene organization, chromosomal locali-
zation, cellular source and ligand-recognition and stimuli-inducing
ability [5].
Some limitations must be conceded here. PTX3 values for day 0
(blood culture day) were not available. Previous study in
meningococcal disease has suggested that PTX3 may already
peak during the first hours after hospital admission, this reflecting
disease severity, which may suggest its utility as an early marker
[8]. Also in vivo studies indicate rapid PTX3 induction following
inflammatory stimulus [5]. However, in the present study several
PTX3 measurements per patient were available (median 2
measurements/patient during days 1 to 4), which reduces the
possibility of bias compared to single measurement protocols. The
present work was not designed to study the effects of antimicrobial
therapy on PTX3 levels. Further research should also assess PTX3
levels in different settings, i.e. in patients with SIRS, in trauma
patients and in viral infections. The prognostic value of PTX3
should also in subsequent studies be compared to that of
procalcitonin. The biological role of PTX3 in bacteremia and
sepsis calls for further elucidation. Possible interactions with
coagulation process and PTX3 also warrant subsequent studies.
Conclusions
In conclusion, PTX3 proved to be a sensitive and specific
independent prognostic marker in patients with bacteremia. It
may serve as a more specific indicator of severe disease than
the other member of the pentraxin superfamily, CRP. PTX3
measurement may offer novel opportunities for the early pro-
gnostic stratification of bacteremia patients in order to target
various therapeutic interventions.
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